(Source: Business Wire)
Ceragenix Pharmaceuticals, Inc.("Ceragenix") (OTCBB:CGXP), a medical device company focused on infectious disease and dermatology, today announced that it has entered into an exclusive evaluation and option to license agreement (the "Agreement") with a global, multi-billion dollar healthcare company covering the use of the Company's Cerashield antimicrobial technology for a specific medical device associated with a high incidence of hospital acquired infections. For competitive reasons, neither the name of the company nor the precise area of interest is being publicly disclosed. Under the terms of the Agreement, the company will have an exclusive period to evaluate, negotiate commercialization terms and license the specified product application for a period of up to seven months. This is the second such agreement entered into by Ceragenix for a medical device application of its CeraShield antimicrobialtechnology.
Mr. Steven Porter, Chairman and CEO of Ceragenix said: "We're very pleased to announce our second development agreement involving our CeraShield antimicrobial coating technology. We believe that attracting a company of this magnitude and caliber is a validation of the potential of our technology."
About Ceragenix
Ceragenix Pharmaceuticals, Inc. is a medical device company focused on infectious disease and dermatology. The Company has two base technology platforms; Ceragenins for treatment of infectious disease and Barrier Repair for the treatment of dermatological disorders including atopic dermatitis, neonatal skin disorders and others. Ceragenin compounds are active against a broad range of gram positive and negative bacteria. We have used our Ceragenin technology to formulate Cerashield antimicrobial coatings for medical devices. All Ceragenin and Cerashield products are currently in the developmental stage. Ceragenix's patented Barrier Repair technology, invented by Dr. Peter Elias, is the platform for the development of EpiCeram® which is currently being marketed by Promius Pharmaceuticals (a wholly owned subsidiary of Dr. Reddy's Laboratories) in the United States under an exclusive supply and distribution agreement. For additional information on Ceragenix, please visit www.ceragenix.com.
FORWARD LOOKING STATEMENTS FOR CERAGENIX.
This press release may contain forward-looking statements.
